Scientific evidence

Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus

Oct 2019

TissueCypher may be a effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.

Author: Frei N, et al.

Publication: Poster presentation (371) at ACG 2019, San Antonio

A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus

Oct 2019

The TissueCypher assay would be cost-effective after five years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.

Author: Hao J, et al.

Publication: ClinicoEconomics and Outcomes Research

An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists

Oct 2019

TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.

Author: Frei N, et al.

Publication: Poster presentation (P1990) at UEG 2019, Barcelona

Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus

Oct 2019

TissueCypher may be an effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.

Author: Frei N, et al.

Publication: Poster presentation (371) at ACG 2019, San Antonio

An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low grade dysplasia at a rate comparable to expert pathologists

Oct 2019

 

TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.

 

Author: Frei N, et al.

Publication: Poster presentation (372) at ACG 2019, San Antonio

Independent validation of a tissue systems pathology test to predict progression in Barrett’s esophagus patients

May 2019

TissueCypher identifies NDBE patients who are at increased risk for progression to HGD/EAC and may benefit from increased surveillance or early intervention.

Author: Davison J, et al.

Publication: Podium presentation (1068) at DDW 2019, San Diego

Clinical experience with a multiplexed immunofluorescence tissue biomarker assay (Tissue Cypher BE) in the management of Barrett’s esophagus: a single center experience

Jun 2018

Use of TissueCypher resulted in clinical “upstaging” occurred in 5 of 46 cases, leading to treatment that otherwise might not be pursued.

Author: Diehl D, et al.

Publication: Poster presentation (Su1109) at DDW 2018, Washington DC

Systems biology approaches in cancer pathology

Jan 2018

A method for objective quantification of epithelial and stromal biomarkers to generate a tissue profile aiding predictive models for cancer pathology.

Author: DeWard A, et al.

Publication: Methods in Molecular Biology

Signatures of field cancerization: a step towards earlier detection of esophageal adenocarcinoma

Aug 2017

Detection of the field effect in the clinical setting with validated, cost-effective diagnostic assays may increase the detection of HGD and EAC.

Author: DeWard AD, et al.

Publication: Translational Cancer Research

A tissue systems pathology test detects abnormalities associated with prevalent high-grade dysplasia and esophageal cancer in Barrett’s esophagus

Feb 2017

A tissue systems pathology test may provide an objective method to facilitate earlier therapeutic intervention of Barrett's esophagus patients.

Author: Critchley-Thorne RJ, et al.

Publication: Cancer Epidemiology, Biomarkers & Prevention

A tissue systems pathology assay for high-risk Barrett’s esophagus

Oct 2016

Exploration of a tissue systems pathology approach to predict progression in patients with non-dysplastic Barrett's esophagus.

Author: Critchley-Thorne RJ, et al.

Publication: Cancer Epidemiology, Biomarkers & Prevention

Individualized risk prediction in Barrett’s esophagus

Jul 2016

Barrett’s esophagus management decisions are often based on subjective diagnoses, so better information and techniques are needed to aid in BE patient care.

Author: DeWard A, et al.

Publication: Medical Laboratory Observer